Results 211 to 220 of about 288,387 (304)

Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness

open access: yesEpilepsia, EarlyView.
This graphical abstract provides an overview of the content from this open‐label extension study of fenfluramine use in patients with Dravet syndrome or Lennox‐Gastaut syndrome. Abstract Objective Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an ...
Antonio Gil‐Nagel   +18 more
wiley   +1 more source

Response to Request for Modification of the 2026 AHA/ASA Acute Ischemic Stroke Guidelines: Endovascular Thrombectomy Imaging Selection in the 6- to 24-Hour Window. [PDF]

open access: yesStroke
Gonzalez NR   +6 more
europepmc   +1 more source

A prospective natural history study protocol for clinical trial readiness in synaptic disorders

open access: yesEpilepsia, EarlyView.
Abstract Objective STXBP1‐related disorder (STXBP1‐RD) and SYNGAP1‐related disorder (SYNGAP1‐RD) are two common genetic synaptopathies that are associated with epilepsy, developmental delay, intellectual developmental disorder, and behavioral problems.
Jillian L. McKee   +38 more
wiley   +1 more source

Effect of time to palliative epilepsy surgery on outcomes

open access: yesEpilepsia, EarlyView.
Abstract Objective Epilepsy duration is a modifiable risk factor in the outcome of definitive epilepsy surgery; however, an analogous effect in palliative procedures has not been shown. We reviewed the Pediatric Epilepsy Surgery Database data for an association between epilepsy duration and seizure reduction in palliative procedures.
Robert M. Crutcher   +34 more
wiley   +1 more source

Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. [PDF]

open access: yesMol Cancer Ther
Yamamoto TM   +9 more
europepmc   +1 more source

Epilepsy‐associated SCN2A‐L1342P mutation drives network hyperexcitability and widespread transcriptomic changes in human cortical organoids

open access: yesEpilepsia, EarlyView.
Abstract Objective SCN2A pathogenic mutations, such as the recurrent heterozygous Nav1.2‐L1342P, are monogenic causes of epilepsy. In this human‐induced pluripotent stem cell–derived model system, we aim to investigate the molecular and cellular mechanisms underlying SCN2A‐L1342P‐associated pathology. Methods Using a human male induced pluripotent stem
Maria I. Olivero‐Acosta   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy